Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will present at
the 2018 Wedbush PacGrow Healthcare Conference in New York next week.
The presentation is scheduled for Tuesday, August 14, 2018 at 2:30 p.m.

The presentation will be webcast. The live and archived webcasts can be
accessed on the “Events” page of the company’s website at

About Omeros Corporation
Omeros is a commercial-stage
biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics for large-market
as well as orphan indications targeting inflammation,
complement-mediated diseases and disorders of the central nervous
system. The company’s drug product OMIDRIA® (phenylephrine
and ketorolac intraocular solution) 1% / 0.3% is marketed for use during
cataract surgery or intraocular lens (IOL) replacement to maintain pupil
size by preventing intraoperative miosis (pupil constriction) and to
reduce postoperative ocular pain. In the European Union, the European
Commission has approved OMIDRIA for use in cataract surgery and other
IOL replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis (pupil constriction), and to reduce postoperative eye
pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development
programs focused on: complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; cognitive impairment; and
addictive and compulsive disorders. In addition, Omeros has a diverse
group of preclinical programs and a proprietary G protein-coupled
receptor (GPCR) platform through which it controls 54 new GPCR drug
targets and corresponding compounds, a number of which are in
preclinical development. The company also exclusively possesses a novel
antibody-generating platform.


Cook Williams Communications, Inc.
Jennifer Cook Williams
and Media Relations